Federation des caisses Desjardins du Quebec’s MiNK Therapeutics INKT Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.84K	Buy	+500	New	+$5.82K	﹤0.01%	2556

Other funds holding INKT

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return

Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's INKT Position: Q2 2026 in Review

Federation des caisses Desjardins du Quebec opened a new position in MiNK Therapeutics (INKT) in Q2 2026: 500 shares worth $5.84K. The stake represents ﹤0.01% of the portfolio and ranks #2556 among its holdings.

27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

Federation des caisses Desjardins du Quebec held 500 shares of MiNK Therapeutics worth $5.84K as of Q2 2026.
MiNK Therapeutics was a new Federation des caisses Desjardins du Quebec position in Q2 2026.
MiNK Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #2556 holding.
27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.